Makindo Medical Notes"One small step for man, one large step for Makindo" |
|
---|---|
Download all this content in the Apps now Android App and Apple iPhone/Pad App | |
MEDICAL DISCLAIMER: The contents are under continuing development and improvements and despite all efforts may contain errors of omission or fact. This is not to be used for the assessment, diagnosis, or management of patients. It should not be regarded as medical advice by healthcare workers or laypeople. It is for educational purposes only. Please adhere to your local protocols. Use the BNF for drug information. If you are unwell please seek urgent healthcare advice. If you do not accept this then please do not use the website. Makindo Ltd. |
Related Subjects: |Differentiation syndrome |Tretinoin (All-trans-retinoic acid (ATRA) ) |Acute Promyelocytic Leukaemia |Acute Myeloblastic Leukaemia (AML)
ATRA has marked a major advance and become the first-choice drug in the treatment of acute promyelocytic leukaemia
Name | Starting Dose | Frequency | Route |
---|---|---|---|
Tretinoin | 45 mg/m2 daily in 2 divided doses maximum duration of treatment is 90 days, consult product literature for details of concomitant chemotherapy. |